Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated ...

RNA specialist Accent Therapeutics has continued a healthy series of funding rounds, raising $75 million in a Series C that was led by Mirae Asset Capital Life Science and supported by Bristol ...